Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ARD-101 for the Treatment of Hyperphagia in Patients With Prader-Willi Syndrome
NCT06828861 is registered in ClinicalTrials.gov with Aardvark Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ARD-101 for the Treatment of Hyperphagia in Patients With Prader-Willi Syndrome
- Lead sponsor
- Aardvark Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 20, 2024
- Completion date
- May 7, 2026
- Enrollment
- 68 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.